GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Debt-to-EBITDA

Pulse Biosciences (Pulse Biosciences) Debt-to-EBITDA : -0.19 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pulse Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.06 Mil. Pulse Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.09 Mil. Pulse Biosciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $-48.92 Mil. Pulse Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.19.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pulse Biosciences's Debt-to-EBITDA or its related term are showing as below:

PLSE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.34   Med: -0.22   Max: -0.14
Current: -0.22

During the past 10 years, the highest Debt-to-EBITDA Ratio of Pulse Biosciences was -0.14. The lowest was -1.34. And the median was -0.22.

PLSE's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs PLSE: -0.22

Pulse Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Pulse Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Debt-to-EBITDA Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -0.23 -0.18 -1.34 -0.22

Pulse Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -2.04 -0.24 -0.21 -0.19

Competitive Comparison of Pulse Biosciences's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Debt-to-EBITDA falls into.



Pulse Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pulse Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.058 + 8.086) / -42.367
=-0.22

Pulse Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.058 + 8.086) / -48.916
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Pulse Biosciences  (NAS:PLSE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pulse Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (Pulse Biosciences) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
Robert W Duggan director, 10 percent owner 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy officer: Chief Commercial Officer 50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson director 3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner officer: CFO & EVP Admin. and Finance CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono director
Ed Ebbers officer: EVP & GM, Dermatology 3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D director C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg director 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow officer: CFO & SVP Admin. and Finance 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588

Pulse Biosciences (Pulse Biosciences) Headlines

From GuruFocus